Charcot-Marie-Tooth Disease Market Report 2026

The charcot-marie-tooth disease market size has grown exponentially in recent years. It will grow from $1.32 billion in 2025 to $1.6 billion in 2026 at a compound annual growth rate (CAGR) of 20.8%. The growth in the historic period can be attributed to genetic disorder awareness, neurology clinic expansion, pain management adoption, physical therapy integration, supportive care focus.

The charcot-marie-tooth disease market size is expected to see exponential growth in the next few years. It will grow to $3.37 billion in 2030 at a compound annual growth rate (CAGR) of 20.5%. The growth in the forecast period can be attributed to gene therapy research, precision neurology, early genetic screening, rare disease funding, patient advocacy initiatives. Major trends in the forecast period include growing focus on symptom management therapies, expansion of genetic testing and diagnosis, increased use of supportive drug treatments, rising research into disease-modifying therapies, growth of multidisciplinary care models.

The surge in healthcare expenditure is expected to drive the growth of the Charcot-Marie-Tooth disease market in the coming years. Healthcare expenditure encompasses spending on medical services, supplies, and activities aimed at maintaining or improving health. Rising healthcare expenditure is primarily driven by the development and adoption of advanced medical technologies, which require significant investment in research, equipment, and specialized training. Increased healthcare spending supports Charcot-Marie-Tooth disease treatment by enabling greater investment in specialized therapies, diagnostic tools, and supportive care, thereby improving access to comprehensive disease management. For instance, in April 2025, according to the Office for National Statistics, a UK-based government agency, healthcare spending increased by 6.5% between 2023 and 2024, compared to a 6.3% rise in 2023. Therefore, the surge in healthcare expenditure is boosting the growth of the Charcot-Marie-Tooth disease market.

Major companies in the Charcot-Marie-Tooth disease market are focusing on developing advanced therapies such as mesenchymal stem cell treatments, which offer ease of isolation and expansion from various tissue sources. Mesenchymal stem cell therapies utilize versatile cells capable of differentiating into multiple tissue types to support nerve repair and reduce inflammation. For example, in March 2025, ENCell Co. Ltd., a South Korea-based biopharmaceutical company, announced that the U.S. Food and Drug Administration granted orphan drug designation to EN001, a mesenchymal stem cell therapy for Charcot-Marie-Tooth (CMT) disease. EN001 aims to repair damaged nerves, enhance the release of therapeutic molecules, and support nerve remyelination. A Phase 1 open-label, dose-escalation clinical study (NCT05333406) involving patients with type 1a CMT assessed the therapy’s safety, tolerability, and optimal dosing over 16 weeks, with participants in the low-dose group receiving an intravenous dose on the first day using a 3+3 trial design.

In November 2024, the Charcot-Marie-Tooth Association (CMTA), a US-based non-profit organization, partnered with the Inherited Neuropathy Consortium (INC) to advance research across the full spectrum of Charcot-Marie-Tooth disease variants. This collaboration accelerates the translation of research into clinical applications, supporting the development of new therapies and offering hope to patients affected by the disease. The Inherited Neuropathy Consortium (INC) is a US-based rare disease clinical research consortium.

Major companies operating in the charcot-marie-tooth disease market are Applied Therapeutics Inc., PTC Therapeutics Inc., Wave Life Sciences Ltd., Atalanta Therapeutics, Taysha Gene Therapies, Passage Bio Inc., Solid Biosciences Inc., Reata Pharmaceuticals, AskBio (Bayer subsidiary), Sarepta Gene Therapy, Forge Biologics, Neurogene Inc., Regenxbio Inc., Bluebird Bio Inc., GenSight Biologics SA, Rocket Pharmaceuticals Inc., Krystal Biotech Inc., Amicus Therapeutics Inc., Orchard Therapeutics plc, Anokion SA, Neurocrine Biosciences Inc., VectivBio Holding AG, Biomarin Pharmaceutical Inc., Travere Therapeutics Inc., Ascendis Pharma A/S.

North America was the largest region in the charcot-marie-tooth disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the charcot-marie-tooth disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the charcot-marie-tooth disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the charcot-marie-tooth disease market by increasing the cost of importing neurological drugs, genetic testing kits, and supportive medical devices used for symptom management. Pain-management drugs, pipeline therapies, and diagnostic services are most affected, particularly in North America and Europe due to dependence on specialized pharmaceutical imports. Online and hospital pharmacy channels face higher procurement costs. However, tariffs are encouraging regional manufacturing of neurology drugs and diagnostic tools, supporting long-term treatment accessibility.

The charcot-marie-tooth disease market research report is one of a series of new reports that provides charcot-marie-tooth disease market statistics, including charcot-marie-tooth disease industry global market size, regional shares, competitors with a charcot-marie-tooth disease market share, detailed charcot-marie-tooth disease market segments, market trends and opportunities, and any further data you may need to thrive in the charcot-marie-tooth disease industry. This charcot-marie-tooth disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Charcot-Marie-Tooth (CMT) disease is a group of inherited neurological disorders that affect the peripheral nerves, which control muscles and transmit sensory information from the limbs to the brain. It is characterized by progressive muscle weakness and wasting, particularly in the feet, lower legs, hands, and forearms, often accompanied by sensory loss, foot deformities (such as high arches or hammertoes), and difficulty walking. CMT is caused by gene mutations that affect the structure or function of peripheral nerves and typically begins in adolescence or early adulthood, though onset and severity can vary.

The main types of Charcot-Marie-Tooth disease include CMT 1, CMT 2, CMT 3, and others. CMT type 1 (CMT 1) is a hereditary neuropathy caused by abnormalities in the myelin sheath surrounding peripheral nerves. Treatments include drug classes such as nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 inhibitors, tricyclic antidepressants, anticonvulsants, analgesics, and pipeline drugs. These medications are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The charcot-marie-tooth disease market consists of revenues earned by entities by providing services such as genetic testing services, physical therapy services, occupational therapy services, and orthotic fitting services. The market value includes the value of related goods sold by the service provider or included within the service offering. The charcot-marie-tooth disease market also includes sales of custom insoles, mobility aids, electrostimulation devices, and compression garments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.